SYNG Pharmaceuticals Announces Issuance of Its Canadian Patent for Non-Hormonal Therapy for Endometriosis

SYNG Pharmaceuticals Inc. (SYNG), a Kingston, Ontario based women’s health biotech, is pleased to announce that on October 04, 2022, the Canadian Intellectual Property Office granted Canada Patent No. 2,903,608 titled, "Treatment of endometriosis, angiogenesis and/or endometrial lesion growth." - October 09, 2022 - SYNG Pharmaceuticals Inc.

New Decentralized Clinical Trial (DCT) Patient Satisfaction and Participation Report

800 Current and Future Clinical Trial Participants Link Satisfaction and Willingness to Participate with Decentralized Strategies - September 21, 2022 - Life Science Strategy Group, LLC

VMRD Begins Manufacturing Key Reagent for Detection of CWD by RT-QuIC

VMRD Begins Manufacturing Key Reagent for Detection of CWD by RT-QuIC

Veterinary Medical Research & Development (VMRD), Pullman, WA, has partnered with CWD Evolution, Fort Collins, CO, to provide state-of-the-art diagnostic reagents for detection of the abnormal prion associated with Chronic Wasting Disease (CWD). The control of CWD requires identification of... - August 09, 2022 - VMRD, Inc.

American Laboratory Products Company Merges with GeneProof

American Laboratory Products Company, Ltd. (“ALPCO”), a specialty in vitro diagnostics company, today announced a merger with GeneProof a.s. (“GeneProof”), a leading molecular diagnostics company based in Brno, Czech Republic. The combination creates a global market leader... - April 21, 2022 - ALPCO

ALPCO Announced Its Support of the Ukrainian People in a Company-Wide Communication to Its Employees

ALPCO (Salem, NH) announced its support of the Ukrainian people in a company-wide communication to its employees. The message outlined the company's contribution to aid refugees through the American Red Cross and Project Hope in the amount of $5,000 each. Additionally, ALPCO is offering an... - March 16, 2022 - ALPCO

Johari Digital Expands Its Horizons for Better Healthcare

Johari Digital Healthcare Ltd. is glad to announce that Johari Digital is expanding to Medical Device Park, Jodhpur, Rajasthan, India. With the expansion, Johari Digital will triple its capacity to uptake challenging projects. Johari welcomes projects from startups as well as Global Med-Tech companies. - March 04, 2022 - Johari Digital Healthcare Ltd.

MacroArray Diagnostics GmbH (MADx) Partners with ALPCO to Offer a Fully Automated Sample-to-Answer Multiplex Allergy Test Solution to the North American Market

ALPCO (Salem, NH), a leading US producer of novel immunoassay testing platforms, recently announced an exclusive distribution partnership with MacroArray Diagnostics GmbH (Vienna, Austria). Together, they offer a comprehensive line of testing solutions for allergies (IgE-based) and food intolerances (IgG-based), from test material to proprietary hardware and software to process and analyze samples. - February 01, 2022 - ALPCO

Johari Digital Healthcare Inaugurated the "Johari Center of Excellence" in IIT Jodhpur Technology Park

Most research and innovations from Academia end up in publications or are shelved, but now with Industry and academia collaboration it will have chance to get converted into a real product through engineering and transfer to manufacturing cycle along with required regulatory compliances. - January 10, 2022 - Johari Digital Healthcare Ltd.

Updated Findings of COVID-19 Impact on Biopharmaceutical Industry & CRO Outsourcing Report

2021 Survey Quantifies Current and Expected impact of COVID-19 on Clinical Development and CRO Outsourcing and Changes Since 2020 - May 25, 2021 - Life Science Strategy Group, LLC

Erica Cai Named ALPCO’s Summer 2020 Diabetes Research Travel Grant Recipient

Erica Cai Named ALPCO’s Summer 2020 Diabetes Research Travel Grant Recipient

Today ALPCO announced Erica Cai from Harvard Medical School as the latest recipient of its Diabetes Research Travel Grant. Dr. Cai is a postdoctoral fellow from the Joslin Diabetes Center researching the mechanism of autoimmunity that leads to beta cell destruction and type 1 diabetes (T1D). Dr. - November 10, 2020 - ALPCO

3Sixty Pharma Solutions Announces Successful Approval of FDA Investigational New Drug Application

3Sixty Pharma Solutions LLC., www.3sixtypharma.com, has announced the successful submission to FDA, and approval of, an Investigational New Drug (IND) Application on behalf of one of its clinical-stage biotech clients. 3Sixty Pharma Solutions’ 360 Start-Up arm continues to be committed to... - October 15, 2020 - 3Sixty Pharma Solutions

Introducing EDI’s COVID-19 Nucleocapsid IgG Quantitative ELISA Kit

The EDI™ COVID-19 Nucleocapsid IgG Quantitative ELISA Kit is designed, developed & produced for the quantitative measurement of human anti-COVID-19 (anti-SARS-CoV-2) IgG antibody in serum. The test uses a series of calibrators & controls in order to determine a standard curve, which allows for specific, concentration-based results of patient samples, giving researchers & healthcare providers access to quantitative patient data in order to better understand a patient's current disease stage. - October 14, 2020 - Epitope Diagnostics, Inc.

Ampersand Capital Partners Acquires American Laboratory Products Company

American Laboratory Products Company, Ltd. (ALPCO), a specialty in vitro diagnostics company, today announced the majority recapitalization of the company by Ampersand Capital Partners. Ampersand’s investment will be used to support ALPCO’s worldwide growth initiatives, including the... - September 21, 2020 - ALPCO

New eClinical Platform Strategic Analysis & Competitive Landscape Report

Survey Quantifies eClinical Platform Use and Satisfaction and Identifies Dramatic Perceptual Changes - August 26, 2020 - Life Science Strategy Group, LLC

Mountain Country Foods Has Partnered with Immunostics, Inc. to Ensure the Health and Safety of Its Employees Through COVID-10 Antibody Testing

Mountain Country Foods Has Partnered with Immunostics, Inc. to Ensure the Health and Safety of Its Employees Through COVID-10 Antibody Testing

Mountain Country Foods has partnered with Immunostics Inc. and Dr. L Scott Benson of the University of Utah School of Medicine to support and maintain a healthy workforce during the COVID-19 crisis. - May 18, 2020 - Immunostics Inc.

New COVID-19 Impact on Biopharmaceutical Industry & CRO Outsourcing Report

Survey Quantifies Current and Expected impact of COVID-19 on Clinical Development and CRO Outsourcing - April 30, 2020 - Life Science Strategy Group, LLC

Marlena Holter Named ALPCO’s Winter 2020 Diabetes Research Travel Grant Recipient

Marlena Holter Named ALPCO’s Winter 2020 Diabetes Research Travel Grant Recipient

ALPCO's Winter 2020 Diabetes Research Travel Grant has been awarded to Marlena Holter, a DVM/PhD candidate from Cornell University’s College of Veterinary Medicine. Ms. Holter’s novel research focuses on GLP-1 regulated glucose regulation following vertical sleeve gastrectomy surgery to define the mechanisms underlying type 2 diabetes remission and metabolic improvement following bariatric surgery. - April 14, 2020 - ALPCO

Immunostics Launches Two Rapid COVID-19 Ab Test Platforms - AFIAS and iChroma COVID-19 Ab Tests

Immunostics Launches Two Rapid COVID-19 Ab Test Platforms - AFIAS and iChroma COVID-19 Ab Tests

Both AFIAS and iChroma COVID-19 Point-of-Care Tests Detect the Novel Coronavirus within 10 Minutes using a whole blood, serum or plasma sample. - April 13, 2020 - Immunostics Inc.

Epitope Diagnostics Has Proudly Introduced Immunoassay Kits Exclusively for the Qualitative Detection of COVID-19

The EDI™ Novel Coronavirus COVID-19 IgG ELISA Kit and EDI™ Novel Coronavirus COVID-19 IgM ELISA Kits. With proven results from clinical testing in China, Epitope Diagnostics, Inc. is eager to cooperate and collaborate to combat the current COVID-19 situation. - March 06, 2020 - Epitope Diagnostics, Inc.

3Sixty Pharma Solutions Partners with Westchester Biotech Project

3Sixty Pharma Solutions Partners with Westchester Biotech Project

Leveraging its “360Start-Up” Powerhouse to Grow a Dynamic Non-Profit for Scientists - January 11, 2020 - 3Sixty Pharma Solutions

3Sixty Pharma Solutions Announces Successful Submission of Start-Up Biotech Investigational New Drug Application

3Sixty Pharma Solutions LLC, www.3sixtypharma.com, last week announced the successful submission to FDA of its first Investigational New Drug (IND) Application on behalf of one of its start-up biotech clients. This news comes on the heels of the formal organization in 2018 of 3Sixty Pharma... - December 16, 2019 - 3Sixty Pharma Solutions

ALPCO Announces Deadline for Winter 2020 Diabetes Research Travel Grant Award

ALPCO Announces Deadline for Winter 2020 Diabetes Research Travel Grant Award

ALPCO announced the submission deadline for its Winter 2020 Diabetes Research Travel Grant Award. Each recipient is awarded up to $2500 to present their research at a relevant conference and a $2500 product credit. - December 04, 2019 - ALPCO

ALPCO Launches Analytically Specific Human and Rodent STELLUX® Glucagon ELISA

ALPCO Launches Analytically Specific Human and Rodent STELLUX® Glucagon ELISA

ALPCO's new STELLUX® Chemiluminescence Glucagon ELISA features increased analytical specificity and a broad range to accurately quantify glucagon levels between 0.86 and 143.7 pmol/L (3-500 pg/mL) in human and rodent samples. - November 06, 2019 - ALPCO

ALPCO’s New Fecal Calprotectin ELISA with Superior Clinical Accuracy Receives FDA 510(k) Clearance

ALPCO’s New Fecal Calprotectin ELISA with Superior Clinical Accuracy Receives FDA 510(k) Clearance

ALPCO received 510(k) clearance from the US FDA for its new fecal Calprotectin Chemiluminescence ELISA test. The ALPCO Calprotectin Chemiluminescence ELISA’s superior clinical accuracy will enable clinical laboratories to provide the most accurate results to gastroenterologists facing the challenges of differentiating IBD from IBS. - October 30, 2019 - ALPCO

New Research Benchmarks Clinical Investigator Satisfaction with Pharma Sponsors and Central Laboratories

8-year Study Tracks Central Lab Performance and Identifies Covance as Leading the Way in Clinical Investigator Satisfaction. - August 13, 2019 - Life Science Strategy Group, LLC

New Research Benchmarks Pharma’s Changing Utilization of Real-World Evidence (RWE) and Its Impact on Contract Research Organizations (CROs)

Study Tracks Utilization of Real-World Data (RWD), Real-World Evidence (RWE) and Supportive Services and Implications to CROs. - June 11, 2019 - Life Science Strategy Group, LLC

ALPCO Announces January 2019 Young Investigator Award Recipient of Its Diabetes Research Travel Grant

ALPCO Announces January 2019 Young Investigator Award Recipient of Its Diabetes Research Travel Grant

ALPCO awards its January 2019 Diabetes Research Travel Grant to Lisa Volpatti at Massachusetts Institute of Technology. - February 05, 2019 - ALPCO

Immunostics Announces the Availability of the Hemochroma PLUS™

Immunostics Announces the Availability of the Hemochroma PLUS™

FDA 510(k) clearance allows Immunostics to market and sell its new hemoglobin analyzer. - January 23, 2019 - Immunostics Inc.

ALPCO Launches FDA Class I Exempt STELLUX® Glucagon ELISA

ALPCO Launches FDA Class I Exempt STELLUX® Glucagon ELISA

ALPCO announces launch of its new highly specific FDA Class I Exempt STELLUX® Chemi Glucagon ELISA. - October 23, 2018 - ALPCO

Epitope Diagnostics, Inc. Certifies Its Total 25-OH Vitamin D EIA Kit Through the CDC’s Vitamin D Standardization-Certification Program (VDSCP)

Epitope Diagnostics, Inc. (EDI), is pleased to announce it has received certification for the Vitamin D Standardization Program (VDSP) for vitamin D measurement in the EDI™ Total 25-OH Vitamin D EIA Kit. CDC’s Vitamin D Standardization-Certification Program (VDSCP) evaluates the... - October 21, 2018 - Epitope Diagnostics, Inc.

ALPCO Announces Inaugural Young Investigators Award Recipient

ALPCO Announces Inaugural Young Investigators Award Recipient

ALPCO announces the first recipient of its new young investigators award, the Diabetes Research Travel Grant. - October 17, 2018 - ALPCO

ALPCO’s Quality Management System Receives ISO 13485:2016 Certification

ALPCO’s Quality Management System Receives ISO 13485:2016 Certification

ALPCO announces that its quality management system recently received the distinguished ISO 13485:2016 certification from Intertek to ensure the quality, safety and efficacy of its products in the clinical diagnostics field. - October 09, 2018 - ALPCO

Epitope Diagnostics, Inc. Joins MetroConnect to Expand International Growth

Epitope Diagnostics, Inc. is pleased to announce it has been selected to take part in MetroConnect 2018, an export assistance program run by the World Trade Center San Diego (WTC) and designed to help San Diego companies accelerate their global growth. This program will allow Epitope Diagnostics... - September 23, 2018 - Epitope Diagnostics, Inc.

ALPCO to Exhibit at the AACC’s 70th Annual Scientific Meeting and Clinical Lab Expo

ALPCO to Exhibit at the AACC’s 70th Annual Scientific Meeting and Clinical Lab Expo

ALPCO will promote the expansion of its STELLUX® Chemiluminescence ELISA platform, as well as its current therapeutic drug monitoring portfolio, gastroenterology testing panel, and assay qualification program at AACC’s 70th Annual Clinical Lab Expo. - July 25, 2018 - ALPCO

ALPCO and InSphero Partner to Offer a Complete Solution to Assess Beta-cell Function in Islet Microtissue Culture Models

ALPCO and InSphero Partner to Offer a Complete Solution to Assess Beta-cell Function in Islet Microtissue Culture Models

ALPCO and InSphero announce partnership to provide customers with a complete solution to assess beta-cell function in islet microtissue culture models. - July 24, 2018 - ALPCO

ALPCO Releases STELLUX® Chemi Active GLP-1 (7-36) Amide ELISA to Accurately Quantify Fasted Levels

ALPCO Releases STELLUX® Chemi Active GLP-1 (7-36) Amide ELISA to Accurately Quantify Fasted Levels

ALPCO, a leading producer of research and clinical immunoassays, recently announced the launch of its STELLUX® Chemi Active GLP-1 (7-36) amide ELISA. The chemiluminescence ELISA features increased sensitivity to accurately quantify active GLP-1 (7-36) amide levels as low as 1.5 pg/mL with a 25... - July 17, 2018 - ALPCO

ALPCO to Feature New STELLUX® Chemi Active GLP-1 (7-36) amide ELISA and Young Investigators Travel Grant Program at ADA’s 78th Scientific Sessions

ALPCO to Feature New STELLUX® Chemi Active GLP-1 (7-36) amide ELISA and Young Investigators Travel Grant Program at ADA’s 78th Scientific Sessions

ALPCO will promote its new STELLUX® Chemi Active GLP-1 (7-36) amide ELISA and Young Investigators Travel Grant Program at the American Diabetes Association’s 78th Scientific Sessions June 22-26, 2018 in Orlando, FL. - June 19, 2018 - ALPCO

CytoTest Boosts Global Sales Team

CytoTest announces the continued expansion of its sales team with the addition of representatives in three major market territories. - January 30, 2018 - CytoTest Inc.

ALPCO to Highlight Assay Qualification Program at the AACC’s 69th Annual Scientific Meeting and Clinical Lab Expo

ALPCO to Highlight Assay Qualification Program at the AACC’s 69th Annual Scientific Meeting and Clinical Lab Expo

ALPCO announced it will feature a variety of products supported by its assay qualification program at the AACC’s 69th Annual Scientific Meeting and Clinical Lab Expo in San Diego August 1-3, 2017. Among these products is the Easy Stool Extraction Device and a Therapeutic Drug Monitoring ELISA portfolio. - July 25, 2017 - ALPCO

Coppe Laboratories Announces Powassan Virus Co-Infection Research in Wisconsin Lyme Patients

Coppe Laboratories conducted patient testing research in Wisconsin among 95 Lyme suspected patients. Within the 95 patient cohort, 41 were tested positive for Lyme disease. Of the 41 tested positive it was demonstrated in the research that approx. 17% of patients were also positive for Powassan Virus. - July 11, 2017 - Coppe Laboratories

ALPCO Offering Demonstrations of STELLUX® Chemiluminescent Plate Reader at ADA's 77th Scientific Sessions

ALPCO Offering Demonstrations of STELLUX® Chemiluminescent Plate Reader at ADA's 77th Scientific Sessions

The STELLUX® Chemiluminescent Plate Reader offers a simple plug-and-play setup, and is the ideal size for any lab. ALPCO’s Field Applications Scientist will be on-site at the ADA’s 77th Scientific Sessions offering live demonstrations of the new STELLUX® Chemiluminescent Plate Reader. - June 07, 2017 - ALPCO

ALPCO and InSphero Collaborate at the ADA's 77th Scientific Sessions to Advance Metabolic Disease Research

ALPCO and InSphero Collaborate at the ADA's 77th Scientific Sessions to Advance Metabolic Disease Research

ALPCO and InSphero will team up at the ADA’s 77th Scientific Sessions to enhance the study of islet function, regeneration, and preservation by providing researchers with methods to perform 3D islet microtissue culture, as well as assays for measuring glucagon secretion and glucose-regulated insulin assays. - June 06, 2017 - ALPCO

ALPCO to Launch New Zonulin ELISAs and Therapeutic Drug Monitoring Assays for IBD at Digestive Disease Week®

ALPCO to Launch New Zonulin ELISAs and Therapeutic Drug Monitoring Assays for IBD at Digestive Disease Week®

ALPCO will launch new gastrointestinal and inflammatory bowel disease (IBD) assays at Digestive Disease Week® May 7-9, 2017 in Chicago, IL. Included in this launch are two Zonulin ELISAs for the study of gut permeability and celiac disease, as well as therapeutic drug monitoring assays for IBD. - May 02, 2017 - ALPCO

New Research Identifies Need for Patient-Centric Clinical Trials and Role for CROs

New Research Identifies Patient-centric Strategies for Clinical Development with over 125 Global Research Opinion Leaders. - April 28, 2017 - Life Science Strategy Group, LLC

New Research Explores Wearable Technology Utilization in Clinical Trials and the Role of CROs

New Report Identifies Current and Future Wearable Technology Utilization and CRO Implications with 130 Clinical Outsourcing Decision Makers. - December 01, 2016 - Life Science Strategy Group, LLC

New Gastrointestinal Pathogen Assays Available from ALPCO

New Gastrointestinal Pathogen Assays Available from ALPCO

ALPCO is now offering a line of research assays for the investigation of common bacterial and parasitic gastrointestinal (GI) pathogens including Giardia lamblia, Cryptosporidium spp., Blastocystis hominis, Entamoeba histolytica/dispar, and Clostridium difficile. These assays can be used to... - November 15, 2016 - ALPCO

New Ultrasensitive Active GLP-1 ELISA to Confidently Measure Fasted Levels of Active GLP-1

New Ultrasensitive Active GLP-1 ELISA to Confidently Measure Fasted Levels of Active GLP-1

ALPCO has released its new STELLUX® Chemiluminescent Ultrasensitive Active GLP-1 ELISA, the most sensitive active GLP-1 assay on the market. - November 09, 2016 - ALPCO

New Research Benchmarks Clinical Investigator Satisfaction with Pharma Sponsors and Central Laboratories

5-year Study Tracks Central Lab Performance and Identifies Opportunities for Pharma Sponsors to Improve Clinical Investigator Satisfaction. - October 24, 2016 - Life Science Strategy Group, LLC

ALPCO Releases Versatile and Economical Chemiluminescent Plate Reader

ALPCO Releases Versatile and Economical Chemiluminescent Plate Reader

ALPCO has launched its new STELLUX® Chemiluminescent Plate Reader, an economical and versatile system for any size lab. - September 20, 2016 - ALPCO

ALPCO’s New and Improved Adiponectin ELISAs Allow Researchers to Confidently Study Type 2 Diabetes

ALPCO’s New and Improved Adiponectin ELISAs Allow Researchers to Confidently Study Type 2 Diabetes

ALPCO has released new and improved versions of their Total Adiponectin and HMW & Total Adiponectin ELISAs which allow researchers to confidently measure adiponectin for the study of high molecular weight (HMW) to total ratios. - August 17, 2016 - ALPCO

Press Releases 1 - 50 of 248